RGD, somatostatin analogs, bombesin, VIP, CCK/gastrin, α-MSH, neurotensin, T140, and exendin-4 are the peptide families most often proposed as vectors for in vivo tumor imaging. This article describes their receptor targets, molecular descriptors, and the tumor types cited for each, distinguishes…
Nine peptide families dominate the supplier literature on receptor-targeted tumor imaging: RGD , bombesin and gastrin-releasing peptide GRP , somatostatin analogs, vasoactive intestinal peptide VIP , cholecystokinin CCK and gastrin peptides, alpha-melanocyte-stimulating hormone α-MSH , neurotensin , T140 derivatives, and exendin-4 . They share one design logic, which the catalog source states directly: a peptide that binds a receptor overexpressed on tumor cells but not on normal cells is a candidate for imaging the tumor. The peptide is the targeting vector, the receptor is the address, and the attached label produces the signal.
Receptor overexpression is necessary but not sufficient. A candidate peptide must also survive long enough in circulation to reach the tumor, clear from blood and healthy organs quickly enough that background signal does not hide the target, and carry its label, typically a radionuclide for positron emission tomography PET or single-photon emission computed tomography SPECT , or a fluorophore for optical imaging, without losing binding affinity. These requirements are why molecular structure matters: chain length, disulfide bonds, cyclization, and amino acid composition all influence stability and clearance. The molecular figures the catalog supplies are the only quantitative information it provides on these points.
The molecular descriptors reported for each family appear below. They describe the specific reference sequences in the catalog, not necessarily every analog sold under the same family name.
| Peptide | Amino acids | Molecular formula | Average MW Da | Primary receptor |
|---|---|---|---|---|
| RGD | 3 | C12H22N6O6 | 346.34 | Integrin αVβ3 |
| Somatostatin | 14 or 28 | Not given | Not given | SSTR1-SSTR5 |
| VIP | 28 | C147H237N43O43S1 | 3326.78 | VPAC1, VPAC2 |
| CCK/gastrin peptide | 8 | C49H61N9O17S3 | 1144.25 | CCK1, CCK2, CCK2i4sv |
| α-MSH | 13 | C75H106N20O19S1 | 1623.83 | MC-1R |
| Neurotensin | 13 12 in source sequence | C78H121N21O20 | 1672.92 | Neurotensin receptors |
| T140 | 14 | C90H143N33O18S2 | 2039.44 | CXCR4 |
| Exendin-4 | 39 | Not given | Not given | GLP-1 receptor |
Two caveats apply to the numbers above. Bombesin and GRP are absent because the catalog gives no molecular formula or molecular weight for them. The catalog also describes neurotensin as a 13-amino-acid peptide yet prints a 12-residue sequence and count; both figures are reproduced here because the source does not reconcile them. The exendin-4 entry, for its part, is truncated mid-sentence, so its described clinical use never appears in full.
RGD is the three-amino-acid peptide arginine-glycine-aspartic acid, with molecular formula C12H22N6O6 and an average molecular weight of 346.34 Da. Its receptors are integrins , a family of cell adhesion molecules built as α/β heterodimers, meaning each receptor carries two subunits, one α and one β. The catalog identifies the αVβ3 integrin as the key target: it is overexpressed on endothelial cells during tumor angiogenesis, is involved in metastasis, and is barely detectable in most normal organs. The contrast between angiogenic endothelium and resting tissue is the basis of the imaging strategy.
Because αVβ3 appears on the endothelial cells of new vessels rather than on the tumor cells themselves, an RGD-based probe images the tumor vasculature. The catalog markets RGD peptides and analogs for this purpose, but it does not specify which format, linear, cyclic, or multimeric, is intended for imaging, how the peptide would be labeled with a detectable moiety, or whether the listed formula refers to the native tripeptide or a derivative. That distinction is not cosmetic. The linear tripeptide, the cyclic form, and a multimeric construct differ in proteolytic stability and in how they engage the integrin dimer, so the molecular weight and formula alone do not tell a buyer which product they are actually handling.
Somatostatins are naturally occurring cyclic peptide hormones of 14 or 28 amino acids. Their native function is inhibitory: somatostatin suppresses the secretion of insulin, glucagon, and other hormones. The catalog identifies five somatostatin receptor subtypes, SSTR1-SSTR5 , and reports that these receptors are overexpressed in several tumor classes, including pancreatic neuroendocrine tumors, small cell lung cancer, and thyroid carcinoma.
Synthetic somatostatin analogs, the catalog states, are used in both imaging and therapy of SSTR-expressing neuroendocrine tumors, and the product list includes octreotide, pasireotide, and vapreotide alongside the native hormones. The catalog does not, however, provide imaging performance data, sensitivity or specificity figures, or citations to human studies in support of any of these claims. That pattern, an assertion of clinical utility with no accompanying evidence, repeats for every family in this survey.
Bombesin and its relatives form a neuropeptide family to which the catalog attributes regulation of exocrine and endocrine secretion, thermoregulation, sucrose regulation, and cell growth. It identifies four bombesin-like receptor subtypes and states that bombesin-like receptors are overexpressed in breast cancer, ovarian cancer, and gastrointestinal stromal tumors. Gastrin-releasing peptide is offered in the same product family, although the catalog text gives it no separate receptor description.
Cholecystokinin and gastrin are structurally and functionally related peptides. Within their identical bioactive regions, the two hormones differ only in the position of tyrosine sulfation: position 6 in gastrin and position 7 in CCK. The 8-amino-acid peptide shown in the catalog, with molecular formula C49H61N9O17S3 and average molecular weight 1144.25 Da, is presented as that shared bioactive sequence. The same entry identifies three CCK receptors, CCK1 , CCK2 , and CCK2i4sv , all members of the G protein-coupled receptor superfamily, and implicates the CCK2/gastrin receptor in human cancers including ovarian stromal tumors and astrocytomas.
The sulfation position is precisely the structural feature that distinguishes the two hormones, and the formula's three sulfur atoms are consistent with the presence of sulfate groups. But a molecular formula cannot show where those groups sit, and the catalog does not state whether its CCK and gastrin products carry the native sulfation pattern. The catalog presents the sulfation position as the only structural difference between the two hormones, making it the feature most likely to determine which receptor a product engages, yet the buyer is given no way to verify it from the product description.
Vasoactive intestinal peptide is a 28-amino-acid neuropeptide with molecular formula C147H237N43O43S1 and average molecular weight 3326.78 Da. It promotes vasodilation and stimulates cell growth through cell surface receptor-mediated signaling, acting through two receptor subtypes, VPAC1 and VPAC2 . The catalog reports high VIP receptor expression in brain tumors, pancreatic adenocarcinomas, and neuroendocrine tumors. It also warns that VIP toxicity can occur even at sub-microgram doses, a limitation the other families do not carry. For imaging, trace quantities are the relevant regime, but the narrow margin the catalog describes positions VIP as a targeting vector rather than a therapeutic.
Alpha-melanocyte-stimulating hormone is a linear tridecapeptide of 13 amino acids, with molecular formula C75H106N20O19S1 and average molecular weight 1623.83 Da. Its native role is regulation of skin pigmentation, and it binds with high affinity to the melanocortin-1 receptor MC-1R . The catalog reports that MC-1R is expressed in over 80% of human melanoma metastases, and it presents α-MSH analogs as carriers for targeted imaging and radiotherapy of melanoma. Prevalence of expression, however, is not the same as expression density, and the catalog gives no data on how much receptor a given lesion carries.
Neurotensin is a 13-amino-acid peptide, according to the catalog's description, with molecular formula C78H121N21O20 and average molecular weight 1672.92 Da. As noted earlier, the catalog's own sequence and count show 12 residues, an internal discrepancy the source does not resolve. The catalog states that neurotensin receptors are expressed in ductal pancreatic adenocarcinoma, small cell lung carcinoma, and medullary thyroid carcinoma, and it offers neurotensin peptides for imaging those tumors. No imaging data accompany the claim.
T140 is a 14-amino-acid peptide containing one disulfide bond, with molecular formula C90H143N33O18S2 and average molecular weight 2039.44 Da. It is an antagonist of CXCR4 , chemokine receptor 4, meaning it occupies the receptor without eliciting the signaling response the native chemokine would provoke. The catalog states that derivatives of T140 have been used as imaging agents for CXCR4-expressing tissues. It does not explain why the antagonist format was chosen, which is a relevant gap: antagonists and agonists engage the same receptor in different ways, and imaging behavior may differ accordingly.
Exendin-4 is a 39-amino-acid peptide hormone with 50% sequence homology to glucagon-like peptide-1 GLP-1 , and it acts as an agonist of the GLP-1 receptor . The catalog's exendin-4 entry is truncated mid-sentence, so whatever clinical use it intended to describe never appears. The one indexed record supplied for this article that bears on the biology of a receptor in this survey is a cross-sectional analysis of US adults in NHANES, which found that GLP-1 receptor agonist use was not independently associated with lower high-sensitivity C-reactive protein after demographic and clinical adjustment β = 0.323, p = 0.38 , indicating no direct anti-inflammatory effect beyond metabolic benefits PMID 41001317 . That study concerns systemic drug effects, not imaging, and it says nothing about whether exendin-4 can visualize GLP-1 receptor-expressing tissues. It is cited here because it is the only supplied record that touches the biology of any of the nine families, and because it illustrates the standard the catalog's imaging claims do not meet.
The catalog behind the claims in this survey is a product list. It supplies molecular descriptors and receptor-expression statements, but no clinical validation: no sensitivity, no specificity, no tumor-to-background ratios, no radiolabeling protocols, and no citations to imaging studies. The indexed literature provided alongside this topic consists of three records, and none of them tests any of the nine peptide families as an in vivo imaging agent. The strongest accurate statement that can be made is that receptor overexpression in the cited tumor types is documented in the catalog; the step from overexpression to a diagnostic image is asserted, not demonstrated.
One supplied record concerns natriuretic peptides, a peptide hormone class used diagnostically in blood rather than as an imaging vector. A cross-sectional analysis of 18,145 healthy US adults from NHANES 1999 to 2004 found that NT-proBNP concentrations differ by age, sex, and race/ethnicity, and estimated that 9.1 million US adults meet the definition for natriuretic peptide deficiency, a state associated with increased cardiometabolic risk PMID 37768244 . The relevance to tumor imaging is indirect but real: peptide biomarker levels vary substantially across demographic groups, and receptor expression plausibly does too. Quantitative imaging studies need population-matched baselines, and a target density that produces clear contrast in one group may not in another.
The second supplied record is a systematic genomic survey of type I secretion systems and their substrate proteins in Salmonella PMID 40662566 . Across 26 strains it identified 61 type I secretion system sets, grouped them into four clusters, predicted 159 potential substrates, and found that certain system genes are transcriptionally co-regulated with virulence genes. The methodological lesson transfers directly: a systematic survey can enumerate a biological system completely, but prediction runs far ahead of validation. The catalog's receptor and tumor-type claims for nine peptide families likewise outnumber the validated imaging applications it documents, which is to say none at all.
What the supplied evidence does not establish: that any peptide listed here achieves diagnostic image contrast in humans; that the clinical use claimed for somatostatin analogs applies equally to all five SSTR subtypes; that MC-1R expression in over 80% of melanoma metastases guarantees a detectable signal in every lesion; that T140 derivatives bind CXCR4 with enough specificity for clean images in vivo; or that exendin-4 has any clinical imaging application whatsoever. These are open questions, and the catalog is silent on each.
The table below consolidates the catalog's receptor and tumor-type claims for the nine families.
| Peptide family | Receptor or target | Tumor types cited in the catalog |
|---|---|---|
| RGD | Integrin αVβ3 | Angiogenic tumor vasculature; involved in metastasis |
| Bombesin / GRP | Bombesin-like receptors 4 subtypes | Breast cancer, ovarian cancer, gastrointestinal stromal tumors |
| Somatostatin | SSTR1-SSTR5 | Pancreatic neuroendocrine tumors, small cell lung cancer, thyroid carcinoma |
| VIP | VPAC1, VPAC2 | Brain tumors, pancreatic adenocarcinomas, neuroendocrine tumors |
| CCK / gastrin | CCK1, CCK2, CCK2i4sv | Ovarian stromal tumors, astrocytomas |
| α-MSH | MC-1R | Melanoma, over 80% of metastases |
| Neurotensin | Neurotensin receptors | Ductal pancreatic adenocarcinoma, small cell lung carcinoma, medullary thyroid carcinoma |
| T140 | CXCR4 | CXCR4-expressing tissues |
| Exendin-4 | GLP-1 receptor | Not specified in the available catalog text |
When choosing among these products, a researcher or buyer can act on the following checks.
The catalog record has three structural limits. It is a product list rather than an evidence review, so every quantitative claim about receptors and tumor types is asserted without citation. It is internally incomplete: the exendin-4 entry is truncated and the neurotensin length is inconsistent. And its list of peptide families is not exhaustive; other targeting peptides exist in the wider literature.
Four questions remain unanswered by anything in this record. Which radiotracers are derived from these peptides, and how are they radiolabeled? What is the clinical status of exendin-4 and GLP-1 receptor-based imaging? Which peptide-receptor pairs have actually been validated in human imaging studies? And how do receptor expression levels compare across tumor types, given that expression density as much as prevalence determines whether a target yields a detectable image? A researcher who needs answers will have to go to the primary imaging literature; neither the catalog nor the indexed records supplied here provide them.
Peptides referenced: Exenatide, VIP (Vasoactive Intestinal Peptide), Octreotide, Pasireotide, Somatostatin, Glucagon, GLP-1.
Related reading: Condensation Agents in SPPS: Mechanisms and Selection, Five Enzyme Families That Build Short Oligopeptides and Peptide Drugs, Animal, Plant and Synthetic Peptides: Sources, Uses and Differences, Common Cosmetic Peptides: Copper, Carnosine, Glutathione, and More.